EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV nanocell platform for targeted cyto-immunotherapy in cancer, said FDA has granted Orphan Drug Designation to EGFR-targeted, doxorubicin-loaded EDV nanocells for the treatment of glioblastoma multiforme.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
